News Releases

Month Year

Month Year

Investor Alerts

Oct 25, 2019

IDEAYA Biosciences to Present at Upcoming Investor Conferences
Oct 8, 2019

IDEAYA Announces First Patient Dosing of IDE196 for Solid Tumors outside of Uveal Melanoma and a Collaboration with Foundation Medicine in support of its Tumor-Agnostic GNAQ/11 Basket Trial
Aug 12, 2019

IDEAYA Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update
Jul 11, 2019

IDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1/2 Tissue-Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations
Jul 9, 2019

IDEAYA Biosciences Strengthens Management with Internal Appointments of Paul Stone, J.D., as Chief Financial Officer, Andres Ruiz Briseno, C.P.A., as Vice President, Finance, and Mick O'Quigley, M.B.A, as Vice President, Development Operations
May 28, 2019

IDEAYA Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
May 22, 2019

IDEAYA Announces Pricing of Initial Public Offering
May 8, 2019

IDEAYA Receives Authorization to Proceed with Phase 1/2 Tissue-Type Agnostic Basket Trial to Treat Patients with Tumors Harboring GNAQ/11 Mutations and PKC Fusions
Mar 29, 2019

Updated Phase 1 Clinical Trial Monotherapy Data for IDE196 in Metastatic Uveal Melanoma to be Presented at AACR Conference
Feb 13, 2019

IDEAYA Biosciences appoints Leading Cancer Researchers Frank McCormick, Ph.D., FRS, and William Sellers, M.D., to Scientific Advisory Board
Jan 2, 2019

IDEAYA Biosciences to Present at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019
Dec 4, 2018

IDEAYA Biosciences, Inc. appoints Bao Truong as Vice President, Head of Regulatory Affairs
Oct 23, 2018

IDEAYA Licenses Phase 1 Compound LXS196 For The Treatment Of Cancers With GNAQ And GNA11 Mutations
Jun 6, 2018

IDEAYA Biosciences to Present at the 2018 Jefferies Global Healthcare Conference
Jun 5, 2018

IDEAYA Biosciences Appoints Paul Stone, J.D., as Senior Vice President and General Counsel, Head of Operations and Mark Lackner, Ph.D. as Vice President, Head of Biomarkers and Synthetic Lethal Biology
Mar 15, 2018

IDEAYA Biosciences Raises $94 Million Crossover Series B Financing

Co-led by Nextech Invest, 6 Dimensions Capital, BVF Partners, and Perceptive Advisors
Mar 13, 2018

IDEAYA Biosciences Appoints Julie Hambleton, M.D., as Senior Vice President and Chief Medical Officer, Head of Development
Mar 13, 2018

IDEAYA Biosciences and Cancer Research UK Announce Partnership Agreement to Develop Small Molecule Inhibitors of PARG

Data related to PARG program to be presented at American Association of Cancer Research (AACR) Annual Meeting
Jan 5, 2018

IDEAYA Biosciences to Present at the 36th Annual J.P. Morgan Healthcare Conference
Sep 6, 2017

IDEAYA Biosciences to Participate in Emerging Innovators Panel at Citi’s 12th Annual Biotech Conference
Sep 16, 2016

FierceBiotech names IDEAYA Biosciences as one of its "Fierce 15" Biotech Companies of 2016
May 3, 2016

IDEAYA Biosciences Raises $46 Million Series A and Recruits Leadership and Advisory Board

- Series A investors include 5AM Ventures, Canaan Partners, Celgene, WuXi Healthcare Ventures, Novartis Institute of Biomedical Research, and Alexandria Real Estate

Show per page